{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T09:15:37Z","timestamp":1790846137371,"version":"4.1.0"},"reference-count":22,"publisher":"American Society of Hematology","issue":"13","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2014,3,27]]},"abstract":"<jats:title>Key Points<\/jats:title>\n               <jats:p>Genetic deletion of JAK2 in vivo shows that MPN cells remain fully dependent on JAK2 signaling for survival. Dual JAK2 targeting with JAK and HSP90 inhibitors offers increased efficacy in murine models and primary samples.<\/jats:p>","DOI":"10.1182\/blood-2014-01-547760","type":"journal-article","created":{"date-parts":[[2014,1,28]],"date-time":"2014-01-28T04:23:25Z","timestamp":1390883005000},"page":"2075-2083","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":104,"title":["Improved targeting of JAK2 leads to increased therapeutic efficacy in myeloproliferative neoplasms"],"prefix":"10.1182","volume":"123","author":[{"given":"Neha","family":"Bhagwat","sequence":"first","affiliation":[{"name":"Human Oncology and Pathogenesis Program,"},{"name":"Gerstner Sloan-Kettering Graduate School in Biomedical Sciences, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priya","family":"Koppikar","sequence":"additional","affiliation":[{"name":"Human Oncology and Pathogenesis Program,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Keller","sequence":"additional","affiliation":[{"name":"Human Oncology and Pathogenesis Program,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sachie","family":"Marubayashi","sequence":"additional","affiliation":[{"name":"Human Oncology and Pathogenesis Program,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaitlyn","family":"Shank","sequence":"additional","affiliation":[{"name":"Human Oncology and Pathogenesis Program,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raajit","family":"Rampal","sequence":"additional","affiliation":[{"name":"Human Oncology and Pathogenesis Program,"},{"name":"Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Qi","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Kleppe","sequence":"additional","affiliation":[{"name":"Human Oncology and Pathogenesis Program,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hardik J.","family":"Patel","sequence":"additional","affiliation":[{"name":"Molecular Pharmacology and Chemistry Program and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Smit K.","family":"Shah","sequence":"additional","affiliation":[{"name":"Molecular Pharmacology and Chemistry Program and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tony","family":"Taldone","sequence":"additional","affiliation":[{"name":"Molecular Pharmacology and Chemistry Program and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James E.","family":"Bradner","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriela","family":"Chiosis","sequence":"additional","affiliation":[{"name":"Molecular Pharmacology and Chemistry Program and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ross L.","family":"Levine","sequence":"additional","affiliation":[{"name":"Human Oncology and Pathogenesis Program,"},{"name":"Gerstner Sloan-Kettering Graduate School in Biomedical Sciences, and"},{"name":"Leukemia Service, Memorial Sloan-Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"9464","key":"2019111816540871100_B1","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/S0140-6736(05)71142-9","article-title":"Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders.","volume":"365","author":"Baxter","year":"2005","journal-title":"Lancet"},{"issue":"7037","key":"2019111816540871100_B2","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1038\/nature03546","article-title":"A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera.","volume":"434","author":"James","year":"2005","journal-title":"Nature"},{"issue":"4","key":"2019111816540871100_B3","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.ccr.2005.03.023","article-title":"Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis.","volume":"7","author":"Levine","year":"2005","journal-title":"Cancer Cell"},{"issue":"17","key":"2019111816540871100_B4","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1056\/NEJMoa051113","article-title":"A gain-of-function mutation of JAK2 in myeloproliferative disorders.","volume":"352","author":"Kralovics","year":"2005","journal-title":"N Engl J Med"},{"issue":"5","key":"2019111816540871100_B5","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1056\/NEJMoa065202","article-title":"JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis.","volume":"356","author":"Scott","year":"2007","journal-title":"N Engl J Med"},{"issue":"7","key":"2019111816540871100_B6","doi-asserted-by":"crossref","first-page":"e270","DOI":"10.1371\/journal.pmed.0030270","article-title":"MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia.","volume":"3","author":"Pikman","year":"2006","journal-title":"PLoS Med"},{"issue":"9","key":"2019111816540871100_B7","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1056\/NEJMoa1110557","article-title":"A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis.","volume":"366","author":"Verstovsek","year":"2012","journal-title":"N Engl J Med"},{"issue":"6","key":"2019111816540871100_B8","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/j.ccr.2010.05.015","article-title":"Physiological Jak2V617F expression causes a lethal myeloproliferative neoplasm with differential effects on hematopoietic stem and progenitor cells.","volume":"17","author":"Mullally","year":"2010","journal-title":"Cancer Cell"},{"issue":"14","key":"2019111816540871100_B9","doi-asserted-by":"crossref","first-page":"2919","DOI":"10.1182\/blood-2009-04-218842","article-title":"Efficacy of the JAK2 inhibitor INCB16562 in a murine model of MPLW515L-induced thrombocytosis and myelofibrosis.","volume":"115","author":"Koppikar","year":"2010","journal-title":"Blood"},{"issue":"7414","key":"2019111816540871100_B10","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1038\/nature11303","article-title":"Heterodimeric JAK-STAT activation as a mechanism of persistence to JAK2 inhibitor therapy.","volume":"489","author":"Koppikar","year":"2012","journal-title":"Nature"},{"issue":"4","key":"2019111816540871100_B11","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1038\/leu.2011.255","article-title":"Kinase domain mutations confer resistance to novel inhibitors targeting JAK2V617F in myeloproliferative neoplasms.","volume":"26","author":"Deshpande","year":"2012","journal-title":"Leukemia"},{"issue":"8","key":"2019111816540871100_B12","doi-asserted-by":"crossref","first-page":"e43437","DOI":"10.1371\/journal.pone.0043437","article-title":"Random mutagenesis reveals residues of JAK2 critical in evading inhibition by a tyrosine kinase inhibitor.","volume":"7","author":"Marit","year":"2012","journal-title":"PLoS ONE"},{"issue":"10","key":"2019111816540871100_B13","doi-asserted-by":"crossref","first-page":"3578","DOI":"10.1172\/JCI42442","article-title":"HSP90 is a therapeutic target in JAK2-dependent myeloproliferative neoplasms in mice and humans.","volume":"120","author":"Marubayashi","year":"2010","journal-title":"J Clin Invest"},{"key":"2019111816540871100_B14","author":"Krempler"},{"issue":"1","key":"2019111816540871100_B15","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1021\/jm0508078","article-title":"Identification of potent water soluble purine-scaffold inhibitors of the heat shock protein 90.","volume":"49","author":"He","year":"2006","journal-title":"J Med Chem"},{"issue":"11","key":"2019111816540871100_B16","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1038\/nchembio.670","article-title":"Affinity-based proteomics reveal cancer-specific networks coordinated by Hsp90.","volume":"7","author":"Moulick","year":"2011","journal-title":"Nat Chem Biol"},{"issue":"3","key":"2019111816540871100_B17","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/S0092-8674(00)81167-8","article-title":"Jak2 is essential for signaling through a variety of cytokine receptors.","volume":"93","author":"Parganas","year":"1998","journal-title":"Cell"},{"issue":"3","key":"2019111816540871100_B18","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/S0092-8674(00)81168-X","article-title":"Jak2 deficiency defines an essential developmental checkpoint in definitive hematopoiesis.","volume":"93","author":"Neubauer","year":"1998","journal-title":"Cell"},{"issue":"6","key":"2019111816540871100_B19","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1158\/2159-8290.CD-11-0324","article-title":"Modulation of activation-loop phosphorylation by JAK inhibitors is binding mode dependent.","volume":"2","author":"Andraos","year":"2012","journal-title":"Cancer Discov"},{"issue":"5531","key":"2019111816540871100_B20","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1126\/science.1062538","article-title":"Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification.","volume":"293","author":"Gorre","year":"2001","journal-title":"Science"},{"issue":"3","key":"2019111816540871100_B21","doi-asserted-by":"crossref","first-page":"e73","DOI":"10.1371\/journal.pmed.0020073","article-title":"Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain.","volume":"2","author":"Pao","year":"2005","journal-title":"PLoS Med"},{"issue":"7397","key":"2019111816540871100_B22","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1038\/nature11016","article-title":"Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia.","volume":"485","author":"Smith","year":"2012","journal-title":"Nature"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/123\/13\/2075\/1374909\/2075.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/123\/13\/2075\/1374909\/2075.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,18]],"date-time":"2019-11-18T21:54:25Z","timestamp":1574114065000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/123\/13\/2075\/32623\/Improved-targeting-of-JAK2-leads-to-increased"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,3,27]]},"references-count":22,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2014,3,27]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2014-01-547760","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,3,27]]}}}